Mydx Research And Development Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 20-12-2024
- Paid Up Capital ₹ 0.10 M
as on 20-12-2024
- Company Age 3 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Revenue %
(FY 2023)
- Ebitda
- Net Worth
- Total Assets 1301.10%
(FY 2023)
About Mydx Research And Development
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Avinash Singh, Nitin Gupta, Ashutosh Pandey, and One other member serve as directors at the Company.
- CIN/LLPIN
U85100DL2021PTC388174
- Company No.
388174
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Oct 2021
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Mydx Research And Development?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ashutosh Pandey  | Director | 25-Mar-2023 | Current |
| Avinash Singh | Director | 12-Oct-2021 | Current |
| Nitin Gupta | Director | 12-Oct-2021 | Current |
| Nitin Arora | Director | 25-Mar-2023 | Current |
Financial Performance of Mydx Research And Development.
Mydx Research And Development Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Mydx Research And Development?
Unlock access to Mydx Research And Development's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Parthasarthi Biolab Private LimitedActive 3 years 10 monthsAshutosh Pandey and Nitin Arora are mutual person
Genenest Biotech Private LimitedActive 4 years 3 monthsAvinash Singh and Nitin Gupta are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Mydx Research And Development?
Mydx Research And Development has a workforce of 0 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Mydx Research And Development, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mydx Research And Development's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
